{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:48:37Z","timestamp":1774054117968,"version":"3.50.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.rmed.2019.06.004","type":"journal-article","created":{"date-parts":[[2019,6,8]],"date-time":"2019-06-08T17:44:49Z","timestamp":1560015889000},"page":"69-75","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility"],"prefix":"10.1016","volume":"154","author":[{"given":"Marc","family":"Humbert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank C.","family":"Albers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel J.","family":"Bratton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven W.","family":"Yancey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark C.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4572-7759","authenticated-orcid":false,"given":"Soichiro","family":"Hozawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7785-6881","authenticated-orcid":false,"given":"Jean-Pierre","family":"Llanos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Namhee","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmed.2019.06.004_bib1","series-title":"Global Strategy for Asthma Management and Prevention","author":"Global Initiative for Asthma","year":"2018"},{"key":"10.1016\/j.rmed.2019.06.004_bib2","series-title":"Asthma Fact Sheet","author":"WHO","year":"2017"},{"issue":"2","key":"10.1016\/j.rmed.2019.06.004_bib3","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.rmed.2019.06.004_bib4","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40413-018-0192-5","article-title":"Type 2 immunity in asthma","volume":"11","author":"Caminati","year":"2018","journal-title":"World Allergy Organ J"},{"issue":"1","key":"10.1016\/j.rmed.2019.06.004_bib5","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.anai.2015.10.027","article-title":"Overlap of atopic, eosinophilic, and TH2-high asthma phenotypes in a general population with current asthma","volume":"116","author":"Tran","year":"2016","journal-title":"Ann. Allergy Asthma Immunol."},{"issue":"4","key":"10.1016\/j.rmed.2019.06.004_bib6","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00281-016-0556-2","article-title":"Type 2 innate lymphoid cells: at the cross-roads in allergic asthma","volume":"38","author":"van Rijt","year":"2016","journal-title":"Semin. Immunopathol."},{"issue":"5","key":"10.1016\/j.rmed.2019.06.004_bib7","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/j.1365-2222.2011.03929.x","article-title":"Severe asthma: from characteristics to phenotypes to endotypes","volume":"42","author":"Wenzel","year":"2012","journal-title":"Clin. Exp. Allergy"},{"issue":"2","key":"10.1016\/j.rmed.2019.06.004_bib8","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/02770903.2017.1322611","article-title":"Biologic treatment eligibility for real-world patients with severe asthma: the IDEAL study","volume":"55","author":"Albers","year":"2018","journal-title":"J. Asthma"},{"issue":"1","key":"10.1016\/j.rmed.2019.06.004_bib9","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s40413-016-0130-3","article-title":"Therapeutic interventions in severe asthma","volume":"9","author":"Canonica","year":"2016","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.rmed.2019.06.004_bib10","author":"Genentech, Omalizumab (XOLAIR)"},{"issue":"9","key":"10.1016\/j.rmed.2019.06.004_bib11","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-154-9-201105030-00002","article-title":"Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial","volume":"154","author":"Hanania","year":"2011","journal-title":"Ann. Intern. Med."},{"issue":"4","key":"10.1016\/j.rmed.2019.06.004_bib12","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1365-2222.2004.1916.x","article-title":"011 International Study, Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma","volume":"34","author":"Holgate","year":"2004","journal-title":"Clin. Exp. Allergy"},{"issue":"3","key":"10.1016\/j.rmed.2019.06.004_bib13","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1398-9995.2004.00772.x","article-title":"Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE","volume":"60","author":"Humbert","year":"2005","journal-title":"Allergy"},{"issue":"8","key":"10.1016\/j.rmed.2019.06.004_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-011857","article-title":"Impact of omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK multicentre observational study (the APEX II study)","volume":"6","author":"Niven","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.rmed.2019.06.004_bib15","author":"GlaxoSmithKline, Mepolizumab (NUCALA)"},{"key":"10.1016\/j.rmed.2019.06.004_bib16","author":"GlaxoSmithKline UK, Mepolizumab (NUCALA)"},{"issue":"13","key":"10.1016\/j.rmed.2019.06.004_bib17","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.rmed.2019.06.004_bib18","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"13","key":"10.1016\/j.rmed.2019.06.004_bib19","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.rmed.2019.06.004_bib20","doi-asserted-by":"crossref","first-page":"AB402","DOI":"10.1016\/j.jaci.2017.12.964","article-title":"Efficacy and safety of mepolizumab in uncontrolled patients with severe eosinophilic asthma following a switch from omalizumab (OSMO study): asthma control, quality of life and lung function outcomes","volume":"141","author":"Albers","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"issue":"2","key":"10.1016\/j.rmed.2019.06.004_bib21","doi-asserted-by":"crossref","first-page":"AB409","DOI":"10.1016\/j.jaci.2017.12.965","article-title":"Efficacy and safety of mepolizumab in uncontrolled patients with severe eosinophilic asthma following a switch from omalizumab (OSMO study): exacerbation and safety outcomes","volume":"141","author":"Galkin","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"issue":"9","key":"10.1016\/j.rmed.2019.06.004_bib22","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1111\/all.12914","article-title":"Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment","volume":"71","author":"Magnan","year":"2016","journal-title":"Allergy"},{"key":"10.1016\/j.rmed.2019.06.004_bib23","author":"GSK, GSK Clinical Studies Register"},{"issue":"6","key":"10.1016\/j.rmed.2019.06.004_bib24","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.jaci.2017.10.005","article-title":"Biomarkers for severe eosinophilic asthma","volume":"140","author":"Yancey","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"issue":"5","key":"10.1016\/j.rmed.2019.06.004_bib25","article-title":"A. expert group of the European Consensus Meeting for Severe Eosinophilic, Severe eosinophilic asthma: a roadmap to consensus","volume":"49","author":"Buhl","year":"2017","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.rmed.2019.06.004_bib26","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1183\/09031936.00220413","article-title":"The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia","volume":"44","author":"Ortega","year":"2014","journal-title":"Eur. Respir. J."},{"issue":"12","key":"10.1016\/j.rmed.2019.06.004_bib27","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1111\/j.1398-9995.2009.02119.x","article-title":"Relationship between pretreatment specific IgE and the response to omalizumab therapy","volume":"64","author":"Wahn","year":"2009","journal-title":"Allergy"},{"issue":"4","key":"10.1016\/j.rmed.2019.06.004_bib28","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1378\/chest.125.4.1378","article-title":"Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma","volume":"125","author":"Bousquet","year":"2004","journal-title":"Chest"},{"issue":"7","key":"10.1016\/j.rmed.2019.06.004_bib29","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.rmed.2007.01.011","article-title":"Predicting and evaluating response to omalizumab in patients with severe allergic asthma","volume":"101","author":"Bousquet","year":"2007","journal-title":"Respir. Med."},{"issue":"9842","key":"10.1016\/j.rmed.2019.06.004_bib30","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.rmed.2019.06.004_bib31","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S2213-2600(16)30031-5","article-title":"Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies","volume":"4","author":"Ortega","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"6","key":"10.1016\/j.rmed.2019.06.004_bib32","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01782-2017","article-title":"Care pathways for the selection of a biologic in severe asthma","volume":"50","author":"Bousquet","year":"2017","journal-title":"Eur. Respir. J."},{"issue":"8","key":"10.1016\/j.rmed.2019.06.004_bib33","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1164\/rccm.201208-1414OC","article-title":"Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study","volume":"187","author":"Hanania","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2019.06.004_bib34","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2147\/JAA.S107982","article-title":"Omalizumab for severe asthma: toward personalized treatment based on biomarker profile and clinical history","volume":"11","author":"Tabatabaian","year":"2018","journal-title":"J. Asthma Allergy"},{"issue":"9","key":"10.1016\/j.rmed.2019.06.004_bib35","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1016\/j.clinthera.2016.07.010","article-title":"Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study","volume":"38","author":"Lugogo","year":"2016","journal-title":"Clin. Ther."},{"issue":"5","key":"10.1016\/j.rmed.2019.06.004_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2018.09.033","article-title":"Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma","volume":"143","author":"Khatri","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"issue":"3","key":"10.1016\/j.rmed.2019.06.004_bib37","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.jaip.2017.11.026","article-title":"Evaluation of potential continuation rules for mepolizumab treatment of severe eosinophilic asthma","volume":"6","author":"Gunsoy","year":"2018","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611119301921?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611119301921?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T11:52:46Z","timestamp":1760615566000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611119301921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":37,"alternative-id":["S0954611119301921"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2019.06.004","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2019.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}